Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
- DOI
- 10.1016/s2213-8587(26)00232-9
- Published
- 2026-10
- Container
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/s2213-8587-26-00232-9,
title = {Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial},
author = {Koutaro Yokote and Toshimasa Yamauchi and Tomotaka Shingaki and Rina Chin and Tomonori Oura and Yukiko Nagai and Iichiro Shimomura and Takashi Kadowaki},
year = {2026},
journal = {The Lancet Diabetes \& Endocrinology},
doi = {10.1016/s2213-8587(26)00232-9},
url = {https://doi.org/10.1016/s2213-8587(26)00232-9}
}RIS
TY - JOUR TI - Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial AU - Koutaro Yokote AU - Toshimasa Yamauchi AU - Tomotaka Shingaki AU - Rina Chin AU - Tomonori Oura AU - Yukiko Nagai AU - Iichiro Shimomura AU - Takashi Kadowaki PY - 2026 JO - The Lancet Diabetes & Endocrinology DO - 10.1016/s2213-8587(26)00232-9 UR - https://doi.org/10.1016/s2213-8587(26)00232-9 ER -
APA
Yokote, K., Yamauchi, T., Shingaki, T., Chin, R., Oura, T., Nagai, Y., Shimomura, I., & Kadowaki, T. (2026). Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(26)00232-9
Source records
- crossref · retrieved 2026-11-10T16:53:24.657Z